NurExone Biologic (J90) Ratios

4 Followers

NurExone Biologic Ratios

DE:J90's free cash flow for Q4 2025 was $0.00. For the 2025 fiscal year, DE:J90's free cash flow was decreased by $ and operating cash flow was $0.00. See a summary of the company’s cash flow.

Ratios	TTM	Mar 26	Mar 25	Mar 24	Dec 22
Liquidity Ratios
Current Ratio	―	2.63	4.11	1.04	4.46
Quick Ratio	―	2.63	4.11	1.04	4.46
Cash Ratio	―	2.16	1.76	0.28	4.08
Solvency Ratio	―	-4.68	-7.29	-1.82	-11.68
Operating Cash Flow Ratio	―	-4.56	-12.28	-1.54	-6.38
Short-Term Operating Cash Flow Coverage	―	0.00	0.00	0.00	0.00
Net Current Asset Value	$ ―	$ 1.28M	$ 954.00K	$ 1.00K	$ 1.99M
Leverage Ratios
Debt-to-Assets Ratio	―	0.03	0.01	<0.01	0.02
Debt-to-Equity Ratio	―	0.04	0.02	0.11	0.02
Debt-to-Capital Ratio	―	0.04	0.02	0.10	0.02
Long-Term Debt-to-Capital Ratio	―	0.00	0.00	0.00	0.00
Financial Leverage Ratio	―	1.48	1.39	11.48	1.33
Debt Service Coverage Ratio	―	-198.97	-290.71	-1.20K	-246.12
Interest Coverage Ratio	―	-203.97	-294.65	-1.22K	-230.88
Debt to Market Cap	―	0.00	0.00	0.00	0.00
Interest Debt Per Share	―	<0.01	<0.01	<0.01	<0.01
Net Debt to EBITDA	―	0.33	0.13	0.14	0.30
Profitability Margins
Gross Profit Margin	―	0.00%	0.00%	0.00%	0.00%
EBIT Margin	―	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	―	0.00%	0.00%	0.00%	0.00%
Operating Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Pretax Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Net Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Continuous Operations Profit Margin	―	0.00%	0.00%	0.00%	0.00%
Net Income Per EBT	―	100.00%	99.98%	100.00%	100.00%
EBT Per EBIT	―	100.96%	100.70%	99.51%	107.22%
Return on Assets (ROA)	―	-156.36%	-206.60%	-167.70%	-292.38%
Return on Equity (ROE)	―	-231.47%	-286.37%	-1925.40%	-389.74%
Return on Capital Employed (ROCE)	―	-204.36%	-245.18%	-1395.80%	-347.74%
Return on Invested Capital (ROIC)	―	-201.88%	-244.94%	-1306.07%	-343.97%
Return on Tangible Assets	―	-156.36%	-206.60%	-167.70%	-292.38%
Earnings Yield	―	-16.60%	-17.89%	-36.59%	-75.25%
Efficiency Ratios
Receivables Turnover	―	0.00	0.00	0.00	0.00
Payables Turnover	―	0.00	0.00	0.00	0.00
Inventory Turnover	―	0.00	0.00	0.00	0.00
Fixed Asset Turnover	―	0.00	0.00	0.00	0.00
Asset Turnover	―	0.00	0.00	0.00	0.00
Working Capital Turnover Ratio	―	0.00	0.00	0.00	0.00
Cash Conversion Cycle	―	0.00	0.00	0.00	0.00
Days of Sales Outstanding	―	0.00	0.00	0.00	0.00
Days of Inventory Outstanding	―	0.00	0.00	0.00	0.00
Days of Payables Outstanding	―	0.00	0.00	0.00	0.00
Operating Cycle	―	0.00	0.00	0.00	0.00
Cash Flow Ratios
Operating Cash Flow Per Share	―	-0.06	-0.07	-0.07	-0.10
Free Cash Flow Per Share	―	-0.06	-0.08	-0.07	-0.10
CapEx Per Share	―	<0.01	<0.01	<0.01	<0.01
Free Cash Flow to Operating Cash Flow	―	1.01	1.13	1.04	1.01
Dividend Paid and CapEx Coverage Ratio	―	-82.02	-7.53	-24.51	-74.00
Capital Expenditure Coverage Ratio	―	-82.02	-7.53	-24.51	-74.00
Operating Cash Flow Coverage Ratio	―	-41.77	-148.12	-147.05	-87.45
Operating Cash Flow to Sales Ratio	―	0.00	0.00	0.00	0.00
Free Cash Flow Yield	―	-11.87%	-19.65%	-30.77%	-35.92%
Valuation Ratios
Price-to-Earnings (P/E) Ratio	―	-6.02	-5.59	-2.73	-1.31
Price-to-Sales (P/S) Ratio	―	0.00	0.00	0.00	0.00
Price-to-Book (P/B) Ratio	―	13.94	16.00	52.63	5.18
Price-to-Free Cash Flow (P/FCF) Ratio	―	-8.42	-5.09	-3.25	-2.78
Price-to-Operating Cash Flow Ratio	―	-8.52	-5.77	-3.38	-2.82
Price-to-Earnings Growth (PEG) Ratio	―	-1.72	1.06	0.04	0.02
Price-to-Fair Value	―	13.94	16.00	52.63	5.18
Enterprise Value Multiple	―	-5.91	-5.57	-2.62	-1.04
Enterprise Value	―	36.43M	27.52M	9.43M	8.44M
EV to EBITDA	―	-5.91	-5.57	-2.62	-1.04
EV to Sales	―	0.00	0.00	0.00	0.00
EV to Free Cash Flow	―	-7.98	-4.97	-3.08	-2.16
EV to Operating Cash Flow	―	-8.07	-5.63	-3.20	-2.19
Tangible Book Value Per Share	―	0.03	0.03	<0.01	0.06
Shareholders’ Equity Per Share	―	0.03	0.03	<0.01	0.06
Tax and Other Ratios
Effective Tax Rate	―	0.00	0.00	0.00	0.00
Revenue Per Share	―	0.00	0.00	0.00	0.00
Net Income Per Share	―	-0.08	-0.08	-0.08	-0.22
Tax Burden	―	1.00	1.00	1.00	1.00
Interest Burden	―	1.00	1.00	1.00	1.00
Research & Development to Revenue	―	0.00	0.00	0.00	0.00
SG&A to Revenue	―	0.00	0.00	0.00	0.00
Stock-Based Compensation to Revenue	―	0.00	0.00	0.00	0.00
Income Quality	―	0.71	0.97	0.81	0.47

Currency in USD